Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
9.12.2020 12:00:00 EET | Business Wire | Press release
Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk & Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015.
“The acquisition of Labor Dr. Merk & Kollegen is strengthening our promising pipeline with diverse potential first-in-class cancer immunology and cancer cell directed therapies for patients with hard-to-treat cancer,” said Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “The trusting and highly effective collaboration between our scientists and the Labor Dr. Merk & Kollegen team has already contributed significantly to our progress in viral-based cancer therapies. We will welcome the Labor Dr. Merk & Kollegen team and look forward to jointly advancing our program in this area.”
Boehringer Ingelheim is taking cancer on by strengthening its position in cancer immunology, with a focus on cancer vaccines, oncolytic viruses, T-cell engagers, stromal modulators and myeloid cell modulators by combining its world-class, in-house research and development with that of highly innovative external companies. The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities and capacities by establishing an end-to-end fully integrated center of excellence for virus development and clinical manufacturing. It will add to a series of strategic acquisitions and collaborations over the past years, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are contributing assets that will be further developed at Labor Dr. Merk & Kollegen’s site.
Labor Dr. Merk & Kollegen is a privately-held company founded in 1971. It is headquartered in Ochsenhausen, Germany, close to Boehringer Ingelheim’s Biberach R&D site. As a center of excellence in virology, Labor Dr. Merk & Kollegen has a long track record in GLP and GMP certified biosafety testing. In recent years Labor Dr. Merk & Kollegen established its GMP-virus manufacturing facility. With around 130 highly qualified and specialized employees, the company has built considerable expertise in process development, manufacturing and analytical characterization of viral therapeutics and oncolytic viral therapeutics. Labor Dr. Merk & Kollegen will be integrated with all employees as a new unit into Boehringer Ingelheim’s Development organization and continue to operate at its Ochsenhausen site. A future expansion is planned.
“Following our successful strategic partnership, we are really excited to join forces with Boehringer Ingelheim,” said Dr. Ingrid Rapp, CEO at Labor Dr. Merk & Kollegen. “Boehringer Ingelheim is a truly global pharmaceutical company with excellent R&D capacities. We look forward to taking our next development step in oncology as part of this outstanding team.”
The companies did not disclose the financial terms of the deal. The transaction is subject to the approval of the competition authorities in Germany. Closing will follow thereafter.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/agreement-acquire-labor-dr-merk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005383/en/
Contact information
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026: the Event That Sheds Light on and Accelerates the Global Agri-food Industry21.7.2026 13:10:00 EEST | Press release
With just a few months to go until SIAL Paris 2026 (17–21 October, Paris Nord Villepinte), the trade fair has unveiled the findings of its new SIAL Insights 2026 report, an international analysis identifying ten major trends set to bring about lasting change to food markets and consumer behavior. Compiled using exclusive data from Kantar Food 360™, Circana and ProtéinesXTC, the report highlights a more personalised, functional and experiential approach to food, whilst revealing the new trade-offs consumers are making in the face of economic, health and environmental challenges. The 10 key insights into food in 2026 1. Healthy eating: fuel for a high-performing body Consumers are seeking measurable benefits: protein, fiber, energy, immunity or digestive health. 2. The ‘gut brain’: food for mental wellbeing Sleep, stress management, hormonal balance and cognitive performance now influence dietary choices. 3. Pleasure as a conscious experience Premium taste experiences, bold flavors and c
Sagepath Reply Recognized in the 2026 Gartner® Market Guide for Strategic Website Agencies21.7.2026 11:00:00 EEST | Press release
Sagepath Reply, a digital experience agency part of the Reply Group, has been included in the 2026 Gartner Market Guide for Strategic Website Agencies. This marks the third time Sagepath Reply has been named in the Market Guide, following its previous inclusions in 2023 and 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721481392/en/ Sagepath Reply, a digital experience agency part of the Reply Group, has been included in the 2026 Gartner Market Guide for Strategic Website Agencies. Gartner, a company delivering actionable, objective insight to executives and their teams, defines strategic website agencies as “service providers dedicated to developing website strategies that deliver relevant digital experiences to external audiences. These agencies bundle their strategic marketing services with an array of complementary offerings to support their clients’ needs around website design, development, search value and co
ClickHouse Announced as Principal Partner & Front of Shirt Sponsor of Fulham Football Club21.7.2026 11:00:00 EEST | Press release
Fulham Football Club is proud to announce ClickHouse, a global technology company specialising in real-time analytics, data infrastructure and AI applications, as its newest Principal Partner and Front of Shirt Sponsor of the Men’s First Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721902779/en/ ClickHouse announced as Principal Partner and Front of Shirt Sponsor of Fulham Football Club This multi-year partnership will see ClickHouse take pride of place on the front of the Men’s First Team home, away and third kits. ClickHouse will also feature across Craven Cottage, the Club’s digital channels, matchday assets and a range of supporter-facing experiences throughout the partnership. The Fulham FC home kit will be released on Thursday 23rd July 2026, keep an eye on the Club’s Instagram for updates. Our collaboration reflects Fulham’s continued focus on innovation, performance and delivering engaging experiences for
European Commission Approves Crysvita ® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union21.7.2026 10:00:00 EEST | Press release
Kyowa Kirin EMEA, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151), today announced that the European Commission (EC) has approved an expansion of the indication for Crysvita® (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to include infants from 1 month to 1 year of age across the European Union and European Economic Area. The approval represents an important step forward for infants living with XLH, a rare, progressive genetic disease that can affect skeletal development from an early age. Earlier diagnosis and treatment are considered important in XLH given the potential impact of the disease on skeletal development during infancy and childhood. XLH is a rare, progressive, lifelong genetic disease characterised by phosphate wasting that can impair bone mineralisation from an early age, leading to skeletal deformities, impaired growth and other serious complications. Clinical manifestations of XLH can emerge during infancy and early childhood, with pr
CapVest Completes Acquisition of TSG21.7.2026 10:00:00 EEST | Press release
CapVest Partners LLP (“CapVest”), a leading New York and London based investment firm, today announces that it has completed its acquisition of a majority stake in TSG Solutions (“TSG”), a European leader in technical services for critical energy infrastructure, following receipt of all necessary approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721628079/en/ TSG Headquartered in Paris, France, TSG operates across 30 countries with over 7,000 employees and annual revenues of more than €1.4 billion. The company designs, builds and maintains critical energy infrastructure across Power (HV, MV & LV electrical), Charge, Solar, Battery Energy Storage Systems (BESS), Biofuels and Gas & Biogas. TSG’s multi-energy capabilities, deep technical expertise and extensive geographical coverage underpin longstanding relationships with a diverse base of leading energy infrastructure operators, and position the company to capture
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom